Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations

Tamra Lysaght; Ian Kerridge; Douglas Sipp; Gerard Porter; Benjamin J. Capps

doi:10.1016/j.stem.2013.11.013

Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations

Tamra Lysaght, Ian Kerridge, Douglas Sipp, Gerard Porter, Benjamin J. Capps

Producción científica: Contribución a una revista › Comentario/debate › revisión exhaustiva

20 Citas (Scopus)

Resumen

Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.

Idioma original	English
Páginas (desde-hasta)	647-651
Número de páginas	5
Publicación	Cell Stem Cell
Volumen	13
N.º	6
DOI	https://doi.org/10.1016/j.stem.2013.11.013
Estado	Published - dic. 5 2013
Publicado de forma externa	Sí

Nota bibliográfica

Funding Information:
The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as emergent Forms of Life and Practice” Project, funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).

ASJC Scopus Subject Areas

Molecular Medicine
Genetics
Cell Biology

Acceder al documento

10.1016/j.stem.2013.11.013

Otros archivos y enlaces

Citar esto

@article{425732536ed94932aa9ca4a540d8ca9a,

title = "Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations",

abstract = "Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.",

author = "Tamra Lysaght and Ian Kerridge and Douglas Sipp and Gerard Porter and Capps, {Benjamin J.}",

note = "Funding Information: The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as emergent Forms of Life and Practice” Project, funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).",

year = "2013",

month = dec,

day = "5",

doi = "10.1016/j.stem.2013.11.013",

language = "English",

volume = "13",

pages = "647--651",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Oversight for clinical uses of autologous adult stem cells

T2 - Lessons from international regulations

AU - Lysaght, Tamra

AU - Kerridge, Ian

AU - Sipp, Douglas

AU - Porter, Gerard

AU - Capps, Benjamin J.

N1 - Funding Information: The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as emergent Forms of Life and Practice” Project, funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).

PY - 2013/12/5

Y1 - 2013/12/5

N2 - Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.

AB - Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.

UR - http://www.scopus.com/inward/record.url?scp=84890065690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890065690&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2013.11.013

DO - 10.1016/j.stem.2013.11.013

M3 - Comment/debate

C2 - 24315438

AN - SCOPUS:84890065690

SN - 1934-5909

VL - 13

SP - 647

EP - 651

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 6

ER -

Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto